Spots Global Cancer Trial Database for microcystic lymphatic malformation
Every month we try and update this database with for microcystic lymphatic malformation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | NCT05050149 | Microcystic Lym... | PTX-022 | 13 Years - | Palvella Therapeutics, Inc. | |
| Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations | NCT06160739 | Microcystic Lym... Combined Vascul... Vascular Malfor... | Sirolimus 1Mg O... | 6 Months - 12 Years | Sohag University | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations | NCT06160739 | Microcystic Lym... Combined Vascul... Vascular Malfor... | Sirolimus 1Mg O... | 6 Months - 12 Years | Sohag University | |
| Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | NCT00975819 | Kaposiform Hema... Tufted Angioma Capillary Venou... Venous Lymphati... Microcystic Lym... Mucocutaneous L... Capillary Lymph... PTEN Overgrowth... Lymphangiectasi... | sirolimus | - 31 Years | Children's Hospital Medical Center, Cincinnati | |
| Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | NCT00975819 | Kaposiform Hema... Tufted Angioma Capillary Venou... Venous Lymphati... Microcystic Lym... Mucocutaneous L... Capillary Lymph... PTEN Overgrowth... Lymphangiectasi... | sirolimus | - 31 Years | Children's Hospital Medical Center, Cincinnati | |
| Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations | NCT06160739 | Microcystic Lym... Combined Vascul... Vascular Malfor... | Sirolimus 1Mg O... | 6 Months - 12 Years | Sohag University | |
| Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | NCT05050149 | Microcystic Lym... | PTX-022 | 13 Years - | Palvella Therapeutics, Inc. | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | NCT05948943 | Lymphatic Malfo... | Alpelisib Placebo | 2 Years - | Novartis | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | NCT05948943 | Lymphatic Malfo... | Alpelisib Placebo | 2 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
